Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 19Neoplasms 11Polycystic Ovary Syndrome 9Neoplasm Metastasis 4Multiple Myeloma 4Melanoma 4Vomiting 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Leiomyoma 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Ovarian Neoplasms 2Obesity 2Nausea 2Myofibroma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Leukemia 2Insulin Resistance 2Inflammation 2Infertility, Female 2

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 107Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Tablets × Clear all
NCT00748189 2019-06-25

COMPLEMENT 1

Novartis

Phase 3 Terminated
447 enrolled 32 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡